Erlizumab

Drug Profile

Erlizumab

Alternative Names: Anti-CD18 monoclonal antibody - Genentech; rhuMAb CD18

Latest Information Update: 22 Mar 2001

Price : $50

At a glance

  • Originator Genentech
  • Developer Genentech; PDL BioPharma; Roche
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Myocardial infarction; Shock

Most Recent Events

  • 22 Mar 2001 Anti-CD18 monoclonal antibody is now called erlizumab
  • 24 Jan 2001 A study was added to the adverse events and Ischaemic Heart Disease therapeutic trials sections
  • 24 Jan 2001 A study was added to the pharmacokinetics and Ischaemic Heart Disease and Vascular Disorders pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top